Barclays set a €81.00 ($94.19) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. restated a neutral rating on shares of SUZUKI MTR CORP/ADR in a report on Wednesday, July 17th. Deutsche Bank set a €230.00 ($267.44) target price on adidas and gave the company a neutral rating in a report on Tuesday, May 7th. Morgan Stanley upped their target price on WPP from GBX 1,025 ($13.39) to GBX 1,060 ($13.85) and gave the company an equal weight rating in a report on Wednesday, July 17th. Credit Suisse Group restated a buy rating and set a $90.00 target price on shares of Bayerische Motoren Werke in a report on Thursday. Finally, HSBC set a €101.00 ($117.44) target price on Grenke and gave the company a buy rating in a report on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of Buy and a consensus target price of €82.57 ($96.01).
Shares of Fresenius Medical Care AG & Co. KGaA stock opened at €67.00 ($77.91) on Thursday. The company has a debt-to-equity ratio of 100.05, a quick ratio of 0.67 and a current ratio of 1.02. The company has a market capitalization of $20.45 billion and a P/E ratio of 10.43. The company’s 50 day simple moving average is €68.38. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €55.44 ($64.47) and a 52 week high of €91.74 ($106.67).
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.